Oncology Xagena
The main aim of adjuvant therapy, which is given after an apparently successful primary cancer treatment, is to reduce the risk of local and distant metastatic disease relapse owing to residual breast ...
Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can cause cancer by kicking mitochondria into overdrive and increasing the amount of f ...
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor prognosis and survival. More recently, while new ...
Updated data from the advanced non-small cell lung cancer ( NSCLC ) patient cohort of the ongoing phase 1/2 ECHO-202 trial, evaluating Epacadostat, a selective IDO1 enzyme inhibitor, in combination wi ...
Obesity increases the risk of complications during pediatric procedural sedation. The risk of being underweight has not been evaluated in this arena. Researchers therefore investigated the associa ...
BRAF inhibitor and dual BRAF/MEK inhibitors have been approved for the treatment of BRAF-mutated melanoma. Cutaneous squamous cell carcinoma ( cuSCC ) is an adverse event associated with these drugs ...
Cutaneous squamous cell carcinoma ( CSCC ) develops on the head in 80% of cases. Parotid metastasis is rare, but treatment, which associates surgery and radiation therapy, is heavy and prognosis poor. ...
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or me ...
Platinum-based chemotherapy for patients with progressing ovarian cancer is more effective with a longer time interval from previous Platinum treatment ( Platinum-free interval ). In 1999, it was hy ...
Results from the phase 3 CheckMate -214 trial evaluating Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib ( Sutent ) in patients with previously untreated advanced or metastatic renal ...
Updated results from Cohort G of the phase 2 KEYNOTE-021 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Pemetrexed and Carboplatin ( Pem/Carbo ) in patients ...
Data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with advanced gastric or gastroesoph ...
Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma with disease progre ...
Investigational hunter immune cells engineered to seek out and attack a deadly brain cancer known as glioblastoma ( GBM ) infiltrated patients’ tumors and triggered thousands of more T cells once insi ...
Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its propensity to invade the liver vasculature. Macrovascu ...
